EMA Clears Immunotherapy for Early Gastric and GEJ Cancers

by | Feb 3, 2026 | Health

Spread the love
European regulators have endorsed Imfinzi as part of a perioperative treatment strategy that significantly reduces recurrence and death in early-stage gastric and gastroesophageal junction cancer.
Medscape News Europe

Written By

Written by Albert Pham, News Curator and Blogger

Related Posts

0 Comments